Results 11 to 20 of about 4,078 (132)

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar, Ahmadzadehfar Hojjat   +2 more
exaly   +3 more sources

The evolving role of targeted radioligand therapy in small cell and non-small cell lung cancer: a systematic review [PDF]

Exploration of Targeted Anti-tumor Therapy
Background: Targeted radioligand therapy (TRT) is an emerging theranostic modality in oncology. While well established in neuroendocrine and prostate cancers, its role in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) remains ...
Serin Moghrabi, Saad Ruzzeh, Kamal Al-Rabi, Ahmed Abdlkadir, Mohammed J. Al-Jaghbeer, Nouraldeen Alzorgan, Ula Al Rasheed, Mohammad Alqudah, Akram Al-Ibraheem   +8 more
doaj   +2 more sources

Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
We present a case of recurrent thymic neuroendocrine neoplasm (NEN) in a 43-year-old male, who developed ectopic Cushing syndrome (CS), 8 years after his initial diagnosis.
Monica Majumder, Stephen Clarke, Elizabeth Bernard, Venessa H M Tsang   +3 more
doaj   +2 more sources

Phosphohistone H3 and Ki‐67 as prognostic markers in metastatic small intestinal neuroendocrine tumours: A comparative, retrospective cohort study [PDF]

Journal of Neuroendocrinology, Volume 38, Issue 5, May 2026.
Abstract Ki‐67 index and mitotic count form the basis of grading of small intestinal neuroendocrine tumours (siNET). We hypothesized that the mitosis‐specific marker phosphohistone H3 (PHH3) might better correlate with cancer‐specific survival (CSS) and with response to treatment. We evaluated the association between Ki‐67 index, PHH3‐estimated mitotic
Dimitrios Papantoniou, Malin Grönberg, Eva Tiensuu Janson   +2 more
wiley   +2 more sources

A case report of enduring benefit of sequential PRRT in malignant insulinoma [PDF]

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +2 more sources

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [PDF]

BMC Cancer
Background Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Ameya D. Puranik, Indraja D. Dev, Sushil Yadav, Venkatesh Rangarajan, Archi Agrawal, Sandip Basu, Vikram A. Chaudhari, Anant Ramaswamy, Vikas Ostwal, Manish S. Bhandare, Shailesh V. Shrikhande, Rahul V. Parghane, Prabhat Bhargava, Munita M. Bal, Subhash Yadav, Shraddha Patkar, Mahesh Goel, Nilendu C. Purandare, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Manikandan Venkatachalam   +21 more
doaj   +2 more sources

Recent Therapeutic Advances in Pituitary Carcinoma [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
Pituitary carcinoma (PC) is a rare, aggressive malignancy that comprises 0.1–0.2% of all pituitary tumors. PC is defined anatomically as a pituitary tumor that metastasizes outside the primary intrasellar location as noncontiguous lesions in the central ...
Ian J. Robertson, Timothy A. Gregory, Steven G. Waguespack, Marta Penas-Prado, Nazanin K. Majd   +4 more
doaj   +1 more source

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Journal of Pancreatology, 2023
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj   +1 more source

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

World Journal of Nuclear Medicine, 2021
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy ...
Rahul Parghane, Arpit Mitra, Trupti Bannore, Sutapa Rakshit, Sharmila Banerjee, Sandip Basu   +5 more
doaj   +1 more source